MetaStat, Inc. (MTST)

OTCMKTS · Delayed Price · Currency is USD
0.0010
+0.0003 (42.86%)
At close: May 19, 2026
Market Cap5.88K -99.9%
Revenue (ttm)23.30K
Net Income-3.31M
EPS-0.61
Shares Out 5.88M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume311
Open0.0010
Previous Close0.0007
Day's Range0.0010 - 0.0010
52-Week Range0.0001 - 0.0844
Beta282.90
AnalystsStrong Buy
Price Target11.00 (+1,099,900.0%)
Earnings Daten/a

About MetaStat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid bl... [Read more]

Industry Biotechnology
Sector Healthcare
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol MTST
Full Company Profile